Oncology Medical News about Bortezomib, Multiple myeloma, Polyneuropathy

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Single-agent bortezomib in previously untreated multiple myeloma: Efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy
Journal of Clinical Oncology, 07/20/09

Richardson PG et al. - Single-agent bortezomib is effective in previously untreated myeloma. Baseline myeloma-associated neuropathy seems more common than previously reported, and bortezomib-associated neuropathy, although a common toxicity, is reversible in most patients.

Methods

Main objectives of this study were to:
- Assess efficacy and safety of single-agent bortezomib in previously untreated pts with multiple myeloma
- Investigate prevalence of baseline and treatment-emergent polyneuropathy, and
- Identify molecular markers associated with response and neuropathy
Pts received bortezomib 1.3 mg/m2 on d1, 4, 8, and 11, for up to eight 21-day cycles
A subset of pts underwent neurophysiologic evaluation pre- and post-treatment
Bone marrow aspirates were performed at baseline for exploratory whole-genome analyses

Results

Among 64 pts, 41% had partial response or better, including 9% complete/near-complete responses
Median duration of response was 8.4 mo; RR did not differ in the presence or absence of adverse cytogenetics
After median f/u of 29 mo, median time to progression was 17.3 mo
Median overall survival had not been reached; estimated 1-yr survival was 92%
32 pts successfully underwent optional stem-cell transplantation
Bortezomib treatment was generally well tolerated
At baseline, 20% of pts had sensory polyneuropathy
Sensory polyneuropathy developed during treatment in 64% of pts, resolved in 85% within 98 days
Neurologic examination in 35 pts confirmed pretreatment sensory neuropathy in 20% and new or worsening neuropathy in 63%
Pharmacogenomic analyses identified molecular markers of response and treatment-emergent neuropathy, which will require future study

<< Previous
Quality of life after pelvic radiotherapy or vaginal...

Next >>
Safety, pharmacokinetics, and antitumor activity of AMG 386, a...